• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Wacker wins FDA nod to manufacture active ingredient in Chiesi’s thrombolysis drug

January 9, 2018 By Sarah Faulkner

PillsWacker Biotech said today that it won FDA approval to start producing reteplase, the active ingredient in Chiesi‘s thrombolysis drug, Retavase.

The medication, which is designed to treat acute myocardial infarction in adults, will be marketed in the U.S. by Chiesi and made in Wacker’s Germany-based plant.

Wacker reported that it landed approval to commercially manufacture reteplase for the U.S. market just three months after the FDA inspected its facility.

“We are very pleased with the FDA approval of Chiesi’s product Retavase for the US market. This allows us, as a contract manufacturer, to contribute to the treatment of serious illnesses such as a heart attack,” managing director Susanne Leonhartsberger said in prepared remarks.

“I am very proud of the entire Wacker team that spent years establishing and implementing the required production process at our plant and has now achieved FDA approval for manufacturing, too. This confirms that our plants and processes are fully compliant with the most stringent of requirements. All of our customers can profit from this extensive expertise and know-how – from generating the cell line, to the transfer and optimization of existing manufacturing processes, to commercial market supply.”

“This approval represents a significant milestone in Chiesi’s work to bring Retavase back to the US market,” Alan Roberts, SVP of scientific affairs for Chiesi’s U.S. division, added.  “Wacker is a proven leader in microbial technology.  The collaborative effort and partnership have been outstanding.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Contract Services, Featured, Pharmaceuticals, Vascular Tagged With: chiesigroup, wackerbiotech

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS